The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Targeting p53 for the treatment of cancer
Open accessAbstract
Dysfunction of the TP53 (p53) gene occurs in most if not all human malignancies. Two principal mechanisms are responsible for this dysfunction; mutation and downregulation of wild-type p53 mediated by MDM2/MDM4. Because of its almost universal inactivation in malignancy, p53 is a highly attractive target for the development of new anticancer drugs. Although multiple strategies have been investigated for targeting dysfunctional p53 for cancer treatment, only 2 of these have so far yielded compounds for testing in clinical trials. These strategies include the identification of compounds for reactivating the mutant form of p53 back to its wild-type form and compounds for inhibiting the interaction between wild-type p53 and MDM2/MDM4. Currently, multiple p53-MDM2/MDM4 antagonists are undergoing clinical trials, the most advanced being idasanutlin which is currently undergoing testing in a phase III clinical trial in patients with relapsed or refractory acute myeloid leukemia. Two mutant p53-reactivating compounds have progressed to clinical trials, i.e., APR-246 and COTI-2. Although promising data has emerged from the testing of both MDM2/MDM4 inhibitors and mutant p53 reactivating compounds in preclinical models, it is still unclear if these agents have clinical efficacy. However, should any of the compounds currently being evaluated in clinical trials be shown to have efficacy, it is likely to usher in a new era in cancer treatment, especially as p53 dysfunction is so prevalent in human cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the DBD is the most common location of p53 mutations.17”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [17]
In the citing paper
“The TADs include TAD1 (AA residues 1–40) and TAD2 (AA residues 41–61), which regulate the transcriptional activities of several genes.17”
From p53: from understanding its structure to advances in therapeutic targeting (2026) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138
In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Comprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Modulation of oxidative stress as an anticancer strategy
Gorrini, C., Harris, I. S., & Mak, T. W. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4002 · Cited by 3,579
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain
Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206
TP53 mutations in human cancers: origins, consequences, and clinical use.
Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199
The Role of Oxidative Stress in Carcinogenesis
Klaunig, J. E., & Kamendulis, L. M. (2004) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121851 · Cited by 1,533
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer
Peifer, M., Fernández-Cuesta, L., Sos, M. L., George, J., Seidel, D., Kasper, L. H., Plenker, D., Leenders, F., Sun, R., Zander, T., et al. (2012) · Nature Genetics · doi:10.1038/ng.2396 · Cited by 1,397
The multiple mechanisms that regulate p53 activity and cell fate
Hafner, A., Bulyk, M. L., Jambhekar, A., & Lahav, G. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0110-x · Cited by 1,129
Identification of genomic alterations in oesophageal squamous cell cancer
Song, Y., Li, L., Ou, Y., Gao, Z., Li, E., Li, X., Zhang, W., Wang, J., Xu, L., Zhou, Y., et al. (2014) · Nature · doi:10.1038/nature13176 · Cited by 1,083
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
The evolutionary history of 2,658 cancers
Gerstung, M., Jolly, C., Leshchiner, I., Dentro, S. C., Gonzalez, S., Rosebrock, D., Mitchell, T. J., Rubanova, Y., Anur, P., Yu, K., et al. (2020) · Nature · doi:10.1038/s41586-019-1907-7 · Cited by 1,057
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
Targeting mutant p53 for efficient cancer therapy
Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Yaeger, R., Chatila, W. K., Lipsyc, M. D., Hechtman, J. F., Cercek, A., Sanchez-Vega, F., Jayakumaran, G., Middha, S., Zehir, A., Donoghue, M. T. A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2017.12.004 · Cited by 858
Nogueira, V., Park, Y., Chen, C.-C., Xu, P.-Z., Chen, M.-L., Tonic, I., Unterman, T., & Hay, N. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.11.003 · Cited by 780
Bouaoun, L., Sonkin, D., Ardin, M., Hollstein, M., Byrnes, G., Zavadil, J., & Olivier, M. (2016) · Human Mutation · doi:10.1002/humu.23035 · Cited by 730
Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas
Donehower, L. A., Soussi, T., Korkut, A., Liu, Y., Schultz, A., Cardenas, M., Li, X., Babur, O., Hsu, T.-K., Lichtarge, O., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.001 · Cited by 710
PDL1 Regulation by p53 via miR-34
Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683
The p53 Pathway: Origins, Inactivation in Cancer, and Emerging Therapeutic Approaches
Joerger, A. C., & Fersht, A. R. (2016) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060815-014710 · Cited by 661
Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development
Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571
Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
Targeting antioxidants for cancer therapy
Glasauer, A., & Chandel, N. S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.07.017 · Cited by 499
Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth
Zhu, J., Sammons, M. A., Donahue, G., Dou, Z., Vedadi, M., Getlik, M., Barsyte-Lovejoy, D., Al-awar, R., Katona, B. W., Shilatifard, A., et al. (2015) · Nature · doi:10.1038/nature15251 · Cited by 493
A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
Boettcher, S., Miller, P. G., Sharma, R., McConkey, M., Leventhal, M., Krivtsov, A. V., Giacomelli, A. O., Wong, W., Kim, J., Chao, S., et al. (2019) · Science · doi:10.1126/science.aax3649 · Cited by 441
p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression
Moon, S.-H., Huang, C.-H., Houlihan, S. L., Regunath, K., Freed-Pastor, W. A., Morris, J. P., Tschaharganeh, D. F., Kastenhuber, E. R., Barsotti, A. M., Culp-Hill, R., et al. (2019) · Cell · doi:10.1016/j.cell.2018.11.011 · Cited by 435
TP53 Mutations in Human Cancer: Database Reassessment and Prospects for the Next Decade
Leroy, B., Anderson, M., & Soussi, T. (2014) · Human Mutation · doi:10.1002/humu.22552 · Cited by 408
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Mutant p53 as a target for cancer treatment
Duffy, M. J., Synnott, N. C., & Crown, J. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.06.023 · Cited by 364
Self-citationResults of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia
Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352
MDM4 is a key therapeutic target in cutaneous melanoma
Gembarska, A., Luciani, F., Fedele, C., Russell, E. A., Dewaele, M., Villar, S., Zwolinska, A., Haupt, S., de Lange, J., Yip, D., et al. (2012) · Nature Medicine · doi:10.1038/nm.2863 · Cited by 327
Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation
Liu, D. S., Duong, C. P., Haupt, S., Montgomery, K. G., House, C. M., Azar, W. J., Pearson, H. B., Fisher, O. M., Read, M., Guerra, G. R., et al. (2017) · Nature Communications · doi:10.1038/ncomms14844 · Cited by 321
Clinical Overview of MDM2/X-Targeted Therapies
Burgess, A., Chia, K. M., Haupt, S., Thomas, D., Haupt, Y., & Lim, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00007 · Cited by 315
Targeting the Vulnerability of Glutathione Metabolism in ARID1A-Deficient Cancers
Ogiwara, H., Takahashi, K., Sasaki, M., Kuroda, T., Yoshida, H., Watanabe, R., Maruyama, A., Makinoshima, H., Chiwaki, F., Sasaki, H., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2018.12.009 · Cited by 289
A Stapled p53 Helix Overcomes HDMX-Mediated Suppression of p53
Bernal, F., Wade, M., Godes, M., Davis, T. N., Whitehead, D. G., Kung, A. L., Wahl, G. M., & Walensky, L. D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.024 · Cited by 285
Mutant p53 Aggregates into Prion-like Amyloid Oligomers and Fibrils
Ano Bom, A. P. D., Rangel, L. P., Costa, D. C. F., de Oliveira, G. A. P., Sanches, D., Braga, C. A., Gava, L. M., Ramos, C. H. I., Cepeda, A. O. T., Stumbo, A. C., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.340638 · Cited by 280
APR-246 reactivates mutant p53 by targeting cysteines 124 and 277
Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261
Tisato, V., Voltan, R., Gonelli, A., Secchiero, P., & Zauli, G. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0500-5 · Cited by 256
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Dual inhibition of MDMX and MDM2 as a therapeutic strategy in leukemia
Carvajal, L. A., Neriah, D. B., Senecal, A., Benard, L., Thiruthuvanathan, V., Yatsenko, T., Narayanagari, S.-R., Wheat, J. C., Todorova, T. I., Mitchell, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao3003 · Cited by 249
Targeting the p53–MDM2 interaction to treat cancer
Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204
Prion-like aggregation of mutant p53 in cancer
Silva, J. L., Gallo, C. V. D. M., Costa, D. C. F., & Rangel, L. P. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.04.001 · Cited by 201
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3
Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189
APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Master regulatory role of p63 in epidermal development and disease
Soares, E., & Zhou, H. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2701-z · Cited by 182
DNA repair processes are critical mediators of p53-dependent tumor suppression
Janic, A., Valente, L. J., Wakefield, M. J., Di Stefano, L., Milla, L., Wilcox, S., Yang, H., Tai, L., Vandenberg, C. J., Kueh, A. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0043-5 · Cited by 179
Dual-Site Regulation of MDM2 E3-Ubiquitin Ligase Activity
Wallace, M., Worrall, E., Pettersson, S., Hupp, T. R., & Ball, K. L. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.05.029 · Cited by 173
Kumar, S., Wilkes, D. W., Samuel, N., Blanco, M. A., Nayak, A., Alicea-Torres, K., Gluck, C., Sinha, S., Gabrilovich, D., & Chakrabarti, R. (2018) · Journal of Clinical Investigation · doi:10.1172/jci99673 · Cited by 173
Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
Guo, G., Yu, M., Xiao, W., Celis, E., & Cui, Y. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2832 · Cited by 168
PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance
Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166
Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment
Gupta, A., Shah, K., Oza, M. J., & Behl, T. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.155 · Cited by 165
The many faces of p53: something for everyone
Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163
The C terminus of p53 binds the N-terminal domain of MDM2
Poyurovsky, M. V., Katz, C., Laptenko, O., Beckerman, R., Lokshin, M., Ahn, J., Byeon, I. L., Gabizon, R., Mattia, M., Zupnick, A., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1872 · Cited by 157
p53 Isoforms and Their Implications in Cancer
Vieler, M., & Sanyal, S. (2018) · Cancers · doi:10.3390/cancers10090288 · Cited by 153
Salim, K. Y., Maleki Vareki, S., Danter, W. R., San-Marina, S., & Koropatnick, J. (2106) · Oncotarget · doi:10.18632/oncotarget.9133 · Cited by 148
Liu, Y., Wang, X., Wang, G., Yang, Y., Yuan, Y., & Ouyang, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.05.018 · Cited by 135
Peng, X., Zhang, M., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2017) · Cell Death and Disease · doi:10.1038/cddis.2016.137 · Cited by 134
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017) · Cancers · doi:10.3390/cancers9120172 · Cited by 126
Lindemann, A., Patel, A. A., Silver, N. L., Tang, L., Liu, Z., Wang, L., Tanaka, N., Rao, X., Takahashi, H., Maduka, N. K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0096 · Cited by 124
Attenuating the p53 Pathway in Human Cancers: Many Means to the Same End
Wasylishen, A. R., & Lozano, G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026211 · Cited by 123
Emerging Roles of p53 Family Members in Glucose Metabolism
Itahana, Y., & Itahana, K. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030776 · Cited by 123
Mutant p53: a novel target for the treatment of patients with triple‐negative breast cancer?
Synnott, N. C., Murray, A., McGowan, P. M., Kiely, M., Kiely, P. A., O’Donovan, N., O’Connor, D. P., Gallagher, W. M., Crown, J. P., & Duffy, M. J. (2016) · International Journal of Cancer · doi:10.1002/ijc.30425 · Cited by 116
Self-citationMitochondrial MDM2 Regulates Respiratory Complex I Activity Independently of p53
Arena, G., Cissé, M. Y., Pyrdziak, S., Châtre, L., Riscal, R., Fuentes, M., Arnold, J. J., Kastner, M., Gayte, L., Bertrand‐Gaday, C., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.01.023 · Cited by 111
Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target
Schulz‐Heddergott, R., & Moll, U. M. (2018) · Cancers · doi:10.3390/cancers10060188 · Cited by 108
Structural Biology of the Tumor Suppressor p53 and Cancer‐Associated Mutants
(2007) · Advances in Cancer Research · doi:10.1016/s0065-230x(06)97001-8 · Cited by 106
The Tumorigenic Roles of the Cellular REDOX Regulatory Systems
Castaldo, S. A., Freitas, J. R., Conchinha, N. V., & Madureira, P. A. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/8413032 · Cited by 104
Bidou, L., Bugaud, O., Belakhov, V., Baasov, T., & Namy, O. (2017) · RNA Biology · doi:10.1080/15476286.2017.1285480 · Cited by 101
Mutant p53: One, No One, and One Hundred Thousand
Walerych, D., Lisek, K., & Sal, G. D. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00289 · Cited by 95
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Jung, J., Lee, J. S., Dickson, M. A., Schwartz, G. K., Le Cesne, A., Varga, A., Bahleda, R., Wagner, A. J., Choy, E., de Jonge, M. J., et al. (2016) · Nature Communications · doi:10.1038/ncomms12609 · Cited by 95
Rangel, L. P., Ferretti, G. D. S., Costa, C. L., Andrade, S. M. M. V., Carvalho, R. S., da Costa, D. C. F., & Silva, J. L. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004671 · Cited by 93
Reis, B., Jukofsky, L., Chen, G., Martinelli, G., Zhong, H., So, W. V., Dickinson, M. J., Drummond, M., Assouline, S., Hashemyan, M., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.139717 · Cited by 91
Targeting Therapies for the p53 Protein in Cancer Treatments
Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84
An open-label phase I dose-finding study of APR-246 in hematological malignancies
Deneberg, S., Cherif, H., Lazarevic, V, Andersson, P.-O., von Euler, M., Juliusson, G., & Lehmann, S. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.60 · Cited by 84
MDMX (MDM4), a Promising Target for p53 Reactivation Therapy and BeyondPreprint
Marine, J., & Jochemsen, A. G. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026237 · Cited by 83
Napoli, M., & Flores, E. R. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.384 · Cited by 83
Clinical Outcomes of TP53 Mutations in Cancers
Robles, A. I., Jen, J., & Harris, C. C. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026294 · Cited by 78
McDade, S. S., Patel, D., Moran, M., Campbell, J., Fenwick, K., Kozarewa, I., Orr, N., Lord, C. J., Ashworth, A., & McCance, D. J. (2014) · Nucleic Acids Research · doi:10.1093/nar/gku299 · Cited by 77
COTI-2 reactivates mutant p53 and inhibits growth of triple-negative breast cancer cells
Synnott, N. C., O’Connell, D., Crown, J., & Duffy, M. J. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-019-05435-1 · Cited by 77
Self-citationBerberich, A., Kessler, T., Thomé, C. M., Pusch, S., Hielscher, T., Sahm, F., Oezen, I., Schmitt, L.-M., Ciprut, S., Hucke, N., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1580 · Cited by 75
Meric-Bernstam, F., Saleh, M. N., Infante, J. R., Goel, S., Falchook, G. S., Shapiro, G., Chung, K. Y., Conry, R. M., Hong, D. S., Wang, J. S.-Z., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.2505 · Cited by 75
Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors
Wurz, R. P., & Cee, V. J. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01945 · Cited by 75
Haffo, L., Lu, J., Bykov, V. J. N., Martin, S. S., Ren, X., Coppo, L., Wiman, K. G., & Holmgren, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31048-7 · Cited by 73
Synnott, N. C., Bauer, M. R., Madden, S. F., Murray, A. M., Klinger, R. W., O’Donovan, N., O’Connor, D. P., Gallagher, W. M., Crown, J. P., Fersht, A. R., et al. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.053 · Cited by 72
Self-citationSallman, D. A., Dezern, A. E., Steensma, D. P., Sweet, K. L., Cluzeau, T., Sekeres, M. A., Garcia‐Manero, G., Roboz, G. J., McLemore, A. F., McGraw, K. L., et al. (2018) · Blood · doi:10.1182/blood-2018-99-119990 · Cited by 66
Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1
Hang, W., Yin, Z.-X., Liu, G., Zeng, Q., Shen, X., Sun, Q., Li, D., Jian, Y., Zhang, Y.-H., Wang, Y., et al. (2018) · Oncogene · doi:10.1038/s41388-017-0110-2 · Cited by 65
Alterations of p63 and p73 in Human Cancers
Inoue, K., & Fry, E. A. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_2 · Cited by 64
Jones, R. J., Bjorklund, C. C., Baladandayuthapani, V., Kuhn, D. J., & Orlowski, R. Z. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-0135 · Cited by 61
Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition
Ishizawa, J., Nakamaru, K., Seki, T., Tazaki, K., Kojima, K., Chachad, D., Zhao, R., Heese, L. E., Ma, W., Ma, M. C. J., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-0949 · Cited by 60
Collections of Simultaneously Altered Genes as Biomarkers of Cancer Cell Drug Response
Masica, D. L., & Karchin, R. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3122 · Cited by 50
An Update on MDMX and Dual MDM2/X Inhibitors
Espadinha, M., Barcherini, V., Lopes, E. A., & Santos, M. M. M. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666180604080119 · Cited by 50
Vareki, S. M., Salim, K. Y., Danter, W. R., & Koropatnick, J. D. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191766 · Cited by 46
Patyka, M., Sharifi, Z., Petrecca, K., Mansure, J., Jean-Claude, B., & Sabri, S. (2016) · Oncotarget · doi:10.18632/oncotarget.11197 · Cited by 42
Role of Asparagine Endopeptidase in Mediating Wild-Type p53 Inactivation of Glioblastoma
Lin, Y., Liao, K., Miao, Y., Qian, Z., Fang, Z., Yang, X., Nie, Q., Jiang, G., Liu, J., Yu, Y., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz155 · Cited by 42
Precision treatment for cancer: Role of prognostic and predictive markers
Duffy, M. J., & Crown, J. P. (2014) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2013.865700 · Cited by 41
Self-citationIdentifying the determinants of response to MDM2 inhibition
Saiki, A. Y., Caenepeel, S. R., Cosgrove, E. J., Su, C., Boedigheimer, M. J., & Oliner, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.3116 · Cited by 39
The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site.
Orzol, P., Holčáková, J., Nekulová, M., Nenutil, R., Vojtěšek, B., & Coates, P. J. (2015) · PubMed · doi:10.14670/hh-30.503 · Cited by 39
MDM4 is a rational target for treating breast cancers with mutant p53
Miranda, P. J., Buckley, D., Raghu, D., Pang, J., Takano, E. A., Vijayakumaran, R., Teunisse, A. F. A. S., Posner, A., Procter, T., Herold, M. J., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4877 · Cited by 39
MDM2 promotes genome instability by ubiquitinating the transcription factor HBP1
Cao, Z., Xue, J., Cheng, Y., Wang, J., Liu, Y., Li, H., Jiang, W., Li, G., Gui, Y., & Zhang, X. (2019) · Oncogene · doi:10.1038/s41388-019-0761-2 · Cited by 38
The p53 inhibitor Mdm4 cooperates with multiple genetic lesions in tumourigenesis
Xiong, S., Pant, V., Zhang, Y., Aryal, N. K., You, M. J., Kusewitt, D. F., & Lozano, G. (2016) · The Journal of Pathology · doi:10.1002/path.4854 · Cited by 33
Hoffman-Luca, C. G., Yang, C.-Y., Lü, J., Ziazadeh, D. R., McEachern, D., Debüssche, L., & Wang, S. (2015) · PLoS ONE · doi:10.1371/journal.pone.0128807 · Cited by 29
Mutant p53 and ETS2, a Tale of Reciprocity
Martinez, L. A. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00035 · Cited by 26
MDM2 controls gene expression independently of p53 in both normal and cancer cells
Arena, G., Riscal, R., Linares, L. K., & Cam, L. L. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0156-x · Cited by 21
p53 isoforms change p53 paradigm
Bourdon, J. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.969136 · Cited by 19
Marine, J. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.10.026 · Cited by 11
Restoration of conformation of mutant p53
Green, J. A., Von Euler, M., & Abrahmsen, L. B. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy057 · Cited by 9
The Crusade against Mutant p53: Does the COMPASS Point to the Holy Grail?
Abraham, C. G., & Espinosa, J. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.019 · Cited by 7
Gourley, C., Gabra, H., Vergote, I. B., Basu, B., Brenton, J. D., von Euler, M., Björklund, U., Smith, A., & Green, J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps5605 · Cited by 7
Cited by
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
p53 in ferroptosis regulation: The new weapon for the old guardian
Liu, Y., & Gu, W. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00943-y · Cited by 540
Mutant p53 in cancer: from molecular mechanism to therapeutic modulation
Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-05408-1 · Cited by 494
Targeted therapy for head and neck cancer: signaling pathways and clinical studies
Li, Q., Tie, Y., Alu, A., Ma, X., & Shi, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01297-0 · Cited by 253
Small molecules targeting protein–protein interactions for cancer therapy
Wu, D., Li, Y., Zheng, L., Xiao, H., Ouyang, L., Wang, G., & Sun, Q. (2023) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2023.05.035 · Cited by 71
Metadata
- Authors
- Duffy, M. J., Synnott, N. C., O’Grady, S., & Crown, J.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2022-02
- Volume
- 79
- Pages
- 58-67
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W3046244298
- Cited by
- 349
- References
- 120
- FWCI
- 15.88
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.